The primary objective of this study is to assess the impact of bethanechol therapy on tumor
activity by looking at biomarkers of proliferation, inflammation, and stem cell markers in
post-treatment specimens compared to pre-treatment specimens and compared to other patients
who were not treated with bethanechol prior to surgery. The investigators hypothesize that
treatment with bethanechol will alter nerve conduction within tumors by stimulating the
parasympathetic nervous system and reduce tumor proliferation, reduce macrophage activation,
reduce tumor necrosis factor (TNF) alpha, and decrease human cluster of differentiation 44
(CD44) protein cancer stem cells.
The safety objective is to assess the safety and tolerability of short course bethanechol
prior to surgery and the impact of this treatment on immediate surgical outcomes. The
investigators will assess all treatment-related toxicities with an emphasis on GI side
effects and evaluate the impact of therapy on surgical delays or immediate post-op
complications. All subjects will be contacted 1 week after beginning therapy to assess
toxicity including GI specific toxicity and followed for safety for 30 days following
completion of study medication. The investigators hypothesize that treatment for a minimum of
1 week will be tolerable in this selected patient population and will not interfere with
progression to surgery or lead to increased surgical complications.